Arcturus Therapeutics Ltd. – Filings and Transcripts – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

Financials Filter

ended 03/31/19 Q1

ended 12/31/18 FY 2018 – amended

ended 12/31/18 FY 2018

ended 12/31/17 FY 2017 – amended

ended 12/31/17 FY 2017

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement

Details of business combination or exchange offer – amended

Details of business combination or exchange offer

Registration of securities for employees

Ownership Filter

ARK Investment Management LLC

Brosh Capital L.P.

ARK Investment Management LLC

Kummerfeld Keith C

News Filter

Receives Up to $15 Million Commitment From the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients

Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

Shareholder Vote Results

Announces First Quarter Financial Results and Provides a Corporate Update

Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results

Proxies

No filings in this category.

Other Filter

Confidential treatment order

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Notice of effectiveness